Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

 
• By Sten Stovall
  
T-cells
Merck KGaA says deal lets it stay invested in CAR-T field while focusing its R&D efforts • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business